Nachrichten zur Biogen Inc. Aktie

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100%…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up…

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know…

Biogen Aktie: Übernahme treibt Fantasie - Kursziel steigt auf 245 USD

Vancouver (www.aktiencheck.de) - Biogen-Aktienanalyse von Canaccord Genuity:Die Analysten von Canaccord haben das Kursziel für die Aktie von Biogen Inc. (ISIN:…

Biogen Aktie: Übernahme von Apellis stärkt das Portfolio - Oppenheimer sieht deutlich mehr Potenzial

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Oppenheimer:Die Analysten von Oppenheimer stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Apellis Pharma Aktie: Kursziel auf 41 USD erhöht nach Biogen-Deal

New York (www.aktiencheck.de) - Apellis Pharma-Aktienanalyse von Morgan Stanley:Die Analysten von Morgan Stanley haben das Kursziel für die Apellis Pharma-Aktie…

Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript

…

Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing

…

Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza

BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA…

Market movers: Apellis Pharmaceutical, Unilever, McCormick, Biogen...

…

Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at…

Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio

Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio ?of ?rare-disease medicines.…

BMO reiterates Biogen stock rating on Spinraza approval, trial data

BMO reiterates Biogen stock rating on Spinraza approval, trial data…

Biogen high-dose Spinraza approval seen supporting long-term growth

The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB,…

Biogen reports positive Phase 2 results for lupus skin drug

Biogen reports positive Phase 2 results for lupus skin drug…

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase…

Biogen Aktie: HSBC-Analyst bleibt gnadenlos skeptisch

Bad Marienberg (www.aktiencheck.de) - Biogen: Kursziel 150 USD - und trotzdem bleibt das Rating "reduce"Manche Aktienanalysen sind nur Zahlenspiele. Diese…

Heres Why Biogen Inc. (BIIB) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline

In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in…

Biogen Aktie: (K)ein Muss im Depot?

Bad Marienberg (www.aktiencheck.de) - Biogen: Kurszielerhöhung - Was weiß BMO Capital, was der Markt übersieht?Die Aktie von Biogen Inc. (ISIN:…

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimers treatment…

Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025

Stockholm, Sweden, February 6, 2026 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more

These are the stocks posting the largest moves in midday trading.…

Biogen Aktienanalyse: Startet jetzt die Biotech-Rally 2026? Kursziel 225 USD!

Bad Marienberg (www.aktiencheck.de) - Biogen-Aktienanalyse: Goldman Sachs erhöht Kursziel auf 225 USD – Rückenwind für 2026!Die Goldman Sachs hat am…

Biogen: Competing With Eli Lillys Kisunla, Safety Gives Market Edge

…

Biogen Aktie: Morgan Stanley hebt Kursziel auf 156 USD - Kommt 2026 die Trendwende?

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von Morgan Stanley:Der Analyst Terence Flynn von Morgan Stanley hat das Kursziel für die Biogen-Aktie…

Biogen Aktie: Analystenwarnung! HSBC sieht Risiko für Gewinne

London (www.aktiencheck.de) - Biogen-Aktienanalyse von HSBC:Die Analysten von HSBC stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic A? Protofibrils in CSF

TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript

…

Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen

BERLIN/KÖLN (dpa-AFX) - Schlechte Nachrichten für den US-Hersteller Biogen und seinen japanischen Partner Eisai: Ein…

Nvidia, Microsoft, Apple, Zillow, Biogen: What brokers said this week

…

Biogen shares could climb on Leqembi uptake

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer’s…

Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies By Investing.com

Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies…

Biogen Aktie: Piper Sandler erhöht Kursziel kräftig - doch warum bleibt das Rating "neutral"?

Bad Marienberg (www.aktiencheck.de) - Biogen: Was Anleger jetzt wissen müssenBiogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol: BIIB) gehört…

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

dpa-AFX ProFeed